Literature DB >> 8931498

Protein kinase A phosphorylation of the proteasome: a contribution to the alpha-secretase pathway in human cells.

P Marambaud1, S Wilk, F Checler.   

Abstract

The beta-amyloid precursor protein undergoes a physiological cleavage by alpha-secretase that leads to the release of a secreted C-terminally truncated fragment called APP alpha and likely concomitantly reduces the formation of the amyloidogenic A beta peptide. Here we demonstrate that APP alpha secretion is increased by the protein kinase A (PKA) effectors 8-bromo cyclic AMP and forskolin in human embryonic kidney cells (HK293), and that this can be prevented by a proteasome inhibitor. Furthermore, we establish that PKA effectors but not protein kinase C agonists increase the chymotrypsin-like activity and phosphorylation state of the proteasome in vitro and in vivo in HK293 cells. Altogether, this report demonstrates that the alpha-secretase pathway is under the control of PKA in human cells and that the proteasome likely contributes, either directly or through yet unknown intermediates, to the PKA-stimulated APP alpha secretion in human cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8931498     DOI: 10.1046/j.1471-4159.1996.67062616.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Keeping proteasomes under control--a role for phosphorylation in the nucleus.

Authors:  Zhe Sha; Andreas Peth; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

2.  Post-transcriptional contribution of a cAMP-dependent pathway to the formation of alpha- and beta/gamma-secretases-derived products of beta APP maturation in human cells expressing wild-type and Swedish mutated beta APP.

Authors:  P Marambaud; N Chevallier; K Ancolio; F Checler
Journal:  Mol Med       Date:  1998-11       Impact factor: 6.354

Review 3.  Proteasome dysfunction in cardiomyopathies.

Authors:  Jennifer E Gilda; Aldrin V Gomes
Journal:  J Physiol       Date:  2017-03-16       Impact factor: 5.182

4.  Proteasome inhibitors prevent the degradation of familial Alzheimer's disease-linked presenilin 1 and potentiate A beta 42 recovery from human cells.

Authors:  P Marambaud; K Ancolio; E Lopez-Perez; F Checler
Journal:  Mol Med       Date:  1998-03       Impact factor: 6.354

5.  Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease.

Authors:  K Ancolio; C Dumanchin; H Barelli; J M Warter; A Brice; D Campion; T Frébourg; F Checler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 6.  Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.

Authors:  Natura Myeku; Karen E Duff
Journal:  Trends Mol Med       Date:  2017-12-09       Impact factor: 11.951

7.  The activation of the chymotrypsin-like activity of the proteasome is regulated by soluble adenyl cyclase/cAMP/protein kinase A pathway and required for human sperm capacitation.

Authors:  Héctor Zapata-Carmona; Lina Barón; Lidia M Zuñiga; Emilce Silvina Díaz; Milene Kong; Erma Z Drobnis; Peter Sutovsky; Patricio Morales
Journal:  Mol Hum Reprod       Date:  2019-10-28       Impact factor: 4.025

Review 8.  Proteasome Biology: Chemistry and Bioengineering Insights.

Authors:  Lucia Račková; Erika Csekes
Journal:  Polymers (Basel)       Date:  2020-12-04       Impact factor: 4.329

9.  ASK1 negatively regulates the 26 S proteasome.

Authors:  Ji Won Um; Eunju Im; Joongkyu Park; Yohan Oh; Boram Min; Hyun Jung Lee; Jong Bok Yoon; Kwang Chul Chung
Journal:  J Biol Chem       Date:  2010-09-15       Impact factor: 5.157

Review 10.  Regulating the ubiquitin/proteasome pathway via cAMP-signaling: neuroprotective potential.

Authors:  He Huang; Hu Wang; Maria E Figueiredo-Pereira
Journal:  Cell Biochem Biophys       Date:  2013-09       Impact factor: 2.194

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.